Berger V W, Exner D V
Food and Drug Administration, Rockville, Maryland 20852-1448, USA.
Control Clin Trials. 1999 Aug;20(4):319-27. doi: 10.1016/s0197-2456(99)00014-8.
Lack of concealment of allocation in randomized clinical trials can invite selection bias, which is the preferential enrollment of specific patients into one treatment group over another. For example, patients more likely to respond may be enrolled only when the next treatment to be assigned is known to be the active treatment, and patients less likely to respond may be enrolled only when the next treatment to be assigned is known to be the control. Despite the fact that selection bias can compromise both the internal and external validity of trials, little methodology has been developed for its detection. An investigator may test the success of the randomization by comparing baseline characteristics across treatment groups, but such test is limited by the potential inability of the measured baseline variables to predict response. A new method for detecting selections bias, based on response data only, is developed for the case in which a small block size, and either unmasking of treatment codes or an open-label design, have compromised the concealment of allocation. This new method complements baseline comparisons, and is sensitive to detect selection bias even in situations in which baseline comparisons are not.
随机临床试验中分配方案缺乏隐匿性可能会引发选择偏倚,即特定患者被优先纳入某一治疗组而非另一治疗组。例如,只有当已知下一个分配的治疗为活性治疗时,更可能有反应的患者才会被纳入;而只有当已知下一个分配的治疗为对照时,不太可能有反应的患者才会被纳入。尽管选择偏倚会损害试验的内部和外部有效性,但针对其检测的方法却很少。研究者可能会通过比较各治疗组的基线特征来检验随机化的成功与否,但这种检验受到所测量的基线变量可能无法预测反应的限制。针对小样本量、治疗编码未设盲或开放标签设计导致分配方案隐匿性受损的情况,开发了一种仅基于反应数据检测选择偏倚的新方法。这种新方法是对基线比较的补充,即使在基线比较无法检测出选择偏倚的情况下,它也能敏感地检测出选择偏倚。